Track cost pressure
Identify presentations with rising spend and create intervention plans focused on switching opportunities or formulary alignment.
Explore British National Formulary presentations, drill into dispensing trend data, and identify which pharmacies drive the greatest usage of each medicine.
Active filters
| Presentation | Product | Chemical substance | Chapter | Items dispensed |
|---|---|---|---|---|
|
Haemate P 1,000unit inj vials
0211000I0BMABAM
|
Haemate P | Dried factor VIII fraction | Cardiovascular System | No data available |
|
Haemate P 500unit inj vials
0211000I0BMAAAB
|
Haemate P | Dried factor VIII fraction | Cardiovascular System | No data available |
|
Haemoctin 1,000unit inj vials
0211000I0BRACAD
|
Haemoctin | Dried factor VIII fraction | Cardiovascular System | No data available |
|
Haemoctin 250unit inj vials
0211000I0BRAAAE
|
Haemoctin | Dried factor VIII fraction | Cardiovascular System | No data available |
|
Haemoctin 500unit inj vials
0211000I0BRABAC
|
Haemoctin | Dried factor VIII fraction | Cardiovascular System | No data available |
|
Helixate NexGen 1,000unit inj vials
0211000I0BNACAH
|
Helixate NexGen | Dried factor VIII fraction | Cardiovascular System | No data available |
|
Helixate NexGen 2,000unit inj vials
0211000I0BNADAI
|
Helixate NexGen | Dried factor VIII fraction | Cardiovascular System | No data available |
|
Helixate NexGen 250unit inj vials
0211000I0BNAAAF
|
Helixate NexGen | Dried factor VIII fraction | Cardiovascular System | No data available |
|
Helixate NexGen 500unit inj vials
0211000I0BNABAG
|
Helixate NexGen | Dried factor VIII fraction | Cardiovascular System | No data available |
|
High Purity Factor VIII 1,000u / vWf 1,200u inj vials
0211000I0AABDBD
|
Factor VIII Fraction | Dried factor VIII fraction | Cardiovascular System | No data available |
|
High Purity Factor VIII 1,000unit inj vials
0211000I0AAADAD
|
Factor VIII Fraction | Dried factor VIII fraction | Cardiovascular System | No data available |
|
High Purity Factor VIII 1,500unit / vWf 1,800unit inj vials
0211000I0AAANAN
|
Factor VIII Fraction | Dried factor VIII fraction | Cardiovascular System | No data available |
|
High Purity Factor VIII 2,000u / vWf 2,400u inj vials
0211000I0AABEBE
|
Factor VIII Fraction | Dried factor VIII fraction | Cardiovascular System | No data available |
|
High Purity Factor VIII 250unit inj vials
0211000I0AAAEAE
|
Factor VIII Fraction | Dried factor VIII fraction | Cardiovascular System | No data available |
|
High Purity Factor VIII 350unit inj vials
0211000I0AAAJAJ
|
Factor VIII Fraction | Dried factor VIII fraction | Cardiovascular System | No data available |
|
High Purity Factor VIII 500unit inj vials
0211000I0AAACAC
|
Factor VIII Fraction | Dried factor VIII fraction | Cardiovascular System | No data available |
|
Kogenate Bayer 1,000unit inj vials
0211000I0BDACAH
|
Kogenate | Dried factor VIII fraction | Cardiovascular System | No data available |
|
Kogenate Bayer 2,000unit inj vials
0211000I0BDADAI
|
Kogenate | Dried factor VIII fraction | Cardiovascular System | No data available |
|
Kogenate Bayer 250unit inj vials
0211000I0BDABAF
|
Kogenate | Dried factor VIII fraction | Cardiovascular System | No data available |
|
Kogenate Bayer 3,000unit inj vials
0211000I0BDAEAP
|
Kogenate | Dried factor VIII fraction | Cardiovascular System | No data available |
|
Kogenate Bayer 500unit inj vials
0211000I0BDAAAG
|
Kogenate | Dried factor VIII fraction | Cardiovascular System | No data available |
|
Liberate 350unit inj vials
0211000I0BJAAAJ
|
Liberate | Dried factor VIII fraction | Cardiovascular System | No data available |
|
Liberate 500unit inj vials
0211000I0BJACAC
|
Liberate | Dried factor VIII fraction | Cardiovascular System | No data available |
|
Monoclate-P 1,000unit inj vials
0211000I0BCAAAD
|
Monoclate-P | Dried factor VIII fraction | Cardiovascular System | No data available |
|
Monoclate-P 250unit inj vials
0211000I0BCABAE
|
Monoclate-P | Dried factor VIII fraction | Cardiovascular System | No data available |
Link medicine usage to pharmacy and prescriber behaviour to find optimisation opportunities.
Identify presentations with rising spend and create intervention plans focused on switching opportunities or formulary alignment.
Cross-reference high-volume medicines with local health priorities and prescriber activity to target support programs.